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Insulin resistance and hyperinsulinemia are already present in patients
with incipient renal disease. In uremic patients resistance to the action of
insulin has been documented, but it is not known at what stage of renal
disease it appears. We therefore examined 29 patients with IgA glomer-
ulonephritis (IgAGN) and 21 patients with adult polycystic kidney disease
(ADPKD) in different stages of renal failure, and in addition, healthy
age-matched subjects. Insulin sensitivity and other variables of glucose
metabolism were assessed using a frequent sampling intravenous glucose
tolerance test (minimal-model technique). Glomerular filtration rate
(GFR) was assessed in renal patients using the inulin-clearance technique.
Mean insulin sensitivity index (SI), that is, insulin sensitivity, was signifi-
cantly lower (P , 0.001) in all patients combined than in matched healthy
subjects (N 5 16; 14 males, mean age 42 6 3 years; mean SI 8.6 6 0.8
min21 mU/ml). The mean SI was not significantly different in patients with
renal disease of immune (IgAGN) or non-immune (ADPKD) origin, and
it was not correlated with GFR (r 5 0.01, P , 0.52), intact PTH (r 5
20.23, P , 0.11) or calcitriol concentration (r 5 20.03, P , 0.82).
Consequently, the mean SI was similar in renal patients with GFR within
the normal range (N 5 19; 17 males, mean age 41 6 2 years; mean GFR
119 6 5 ml/min/1.73 m2; mean SI 5.1 6 0.7 min21 mU/ml), in patients with
mild to moderate renal failure (N 5 16; 15 males, 46 6 3 years; 67 6 4
ml/min/1.73 m2; 5.1 6 0.7 min21 mU/ml) and in patients with advanced
renal failure (N 5 15; 13 males, 46 6 3 years; 25 6 2 ml/min/1.73 m2; 4.7 6
0.6 min21 mU/ml). Mean fasted plasma insulin concentration, the area
under the curve for plasma insulin concentration (AUC) and total insulin
delivery (TID) during the glucose tolerance test were significantly higher
in patients than in healthy subjects, reflecting hyperinsulinemia in renal
patients. Further, fasted plasma insulin concentration (r 5 20.32, P ,
0.009), AUC (r 5 20.62, P , 0.0001) and TID (r 5 20.34, P , 0.004) in
patients were significantly correlated with insulin sensitivity (SI). The
present data document that insulin resistance and concomitant hyperin-
sulinemia are present early in the course of renal disease, that is, even in
patients with GFR within the normal range, irrespective of the type of
renal disease. This observation may have potential implications with
respect to the high cardiovascular morbidity and mortality in patients with
renal disease.
Uremia is characterized by resistance to the action of insulin
and this is accompanied by hyperinsulinemia, glucose intolerance
and dyslipidemia [1–5]. An impaired glucose tolerance in patients
with renal failure has been recognized decades ago [6], but only
after the euglycemic clamp technique had become available,
diminished insulin-stimulated glucose uptake, that is, insulin
resistance, could be documented [7]. Alvestrand et al showed that
glucose uptake by extrahepatic tissues is universally reduced in
uremic patients, that is, that insulin resistance is present [8]. It is
only in some patients with more severe reduction of glucose-
induced insulin secretion by b-cells, however, that hyperglycemia
and frankly abnormal glucose tolerance are present [9–12].
The incidence of atherosclerotic cardiovascular complications is
increased in patients with terminal renal failure as compared with
healthy subjects [13]. Frequent presence of lipoprotein abnormal-
ities, atherosclerosis and high cardiovascular death rate have been
noted even in patients with modest renal failure, however [14, 15].
Since insulin resistance and consecutive hyperinsulinemia are
thought to be involved in the development of atherosclerosis [16],
it is of interest at which stage of renal disease the derangements
of glucose metabolism, specifically insulin resistance, develop.
To address this issue, we carried out a cross sectional study to
examine insulin sensitivity (and other variables of glucose metab-
olism) in patients with different degrees of renal function. Patients
with renal disease of immune origin, that is, IgA glomerulone-
phritis (IgAGN), and patients with renal disease of non-immune
origin, that is, adult polycystic kidney disease (ADPKD) were
included. The technique of the frequent sampling intravenous
glucose tolerance test and analysis using the minimal-model
technique were exploited.
METHODS
Participants and protocol
The protocol was approved by the Ethics Committee of the
University of Heidelberg. All participants gave their informed
consent. Fifty Caucasian patients with chronic renal disease
between 20 and 60 years of age were examined; 29 had biopsy
confirmed IgAGN and 21 had ADPKD. Patients with known
diabetes mellitus of any type were excluded from the study.
Patients were allocated into three groups with respect to their
renal function: (i) normal plasma creatinine concentration, that is,
below 1.3 mg/dl, (ii) mild to moderate impairment of renal
function, that is, plasma creatinine concentration between 1.3 and
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3.0 mg/dl, and (iii) advanced renal failure, that is, plasma creati-
nine concentration above 3.0 mg/dl. The three groups of patients
were matched with respect to age, gender, body mass index (BMI)
and type of renal disease (Table 1). All patients studied had stable
renal function for at least six months before the study and none of
them was treated with vitamin D, erythropoietin, fish oil or
immunosuppresive agents. Higher grade proteinuria (that is,
above 1 g/day) was present in 1 of 19 patients with normal renal
function, in 5 of 16 patients with mild to moderate renal failure
and in 11/15 patients with advanced renal failure. Anemia [de-
fined as hemoglobin (Hb) concentration below 12 g/liter] was
present in 9 of 15 patients with advanced renal failure (mean Hb
concentration 10.9 6 0.5 g/liter), but in none of the patients with
normal renal function (15.4 6 0.4 g/liter) or patients with mild to
moderate renal impairment (14.8 6 0.5 g/liter). Drugs with the
potential of confounding the assessment of insulin sensitivity
(such as b-receptor blockers, diuretics, etc.) were washed out for
time periods depending on their half-life of action, that is,
short-acting drugs were withdrawn for at least three days preced-
ing examination, whereas long-acting drugs were washed out for
at least one week prior to examination. Hypertension according to
WHO criteria (that is, above 140/90 mm Hg) was present in 11 of
19 patients with normal renal function, in 13 of 16 patients with
mild to moderate renal failure and in all patients with advanced
renal failure. Mean arterial blood pressure (MAP) after washout
of the antihypertensive drugs was not significantly different in all
three groups of patients, that is, 103 6 3, 107 6 3 and 110 6 3 mm
Hg. For comparison, 16 healthy normotensive subjects between 20
and 60 years of age were also examined. They were matched with
respect to age, gender and BMI to the patients (Table 1).
All participants were examined using a frequently sampled
intravenous glucose tolerance test (FSIGT) with plasma glucose
and insulin measurements. For three days before the test they
adhered to a diet with normal carbohydrate content. They were
examined while in recumbent position in a quiet environment
after an overnight fast of at least 12 hours. After a cannula was
placed in both forearms, blood samples for the measurement of
basal (fasted) plasma glucose and insulin concentrations were
withdrawn. Immediately thereafter an i.v. bolus injection of a 40%
glucose solution was given over three minutes. The glucose load
was 0.3 g/kg body wt in healthy normotensive and normorespon-
sive subjects. It was 0.5 g/kg body wt in patients, in whom lower
responsiveness to a glucose load was expected [9–12, 17]. Blood
samples for measurement of plasma glucose and insulin concen-
trations were withdrawn before and at 1, 2, 3, 5, 8, 10, 15, 20, 25,
30, 40, 50, 60, 75, 90, 120 and 150 minutes after the glucose load.
In addition to the above protocol, glomerular filtration rate
(GFR) was assessed in patients on a separate day using the
steady-state inulin (CIn) infusion clearance technique as described
elsewhere (normal range, 90 to 150 ml/min/1.73 m2) [18]. Further,
blood samples for measurement of plasma intact parathyroid
hormone (PTH), 1,25(OH)D3 (calcitriol) and standard bicarbon-
ate concentrations were drawn in all patients.
Measurements and calculations
Plasma glucose concentrations were measured with the Glu-
coanalyzer II® (Beckmann Instruments GmbH, Munich, Ger-
many) and plasma insulin concentrations immuno-enzymatically
using an ELISA with monoclonal insulin antibodies (ES 22®;
Boehringer Mannheim, Mannheim, Germany; normal range, 4 to
16 mU/ml). The cross reactivity with proinsulin was less than 10%
(as compared with a double sandwich RIA) and less than 1% for
C-peptide. The intraassay and interassay coefficient of variation in
healthy subjects is 5.2% and 7.5%, respectively, as assessed by 20
measurements of pooled random samples of healthy volunteers
(N 5 10). Parathyroid hormone (PTH) was measured with an
immuno-radiometric assay (normal range, 1.2 to 6.0 pmol/liter),
calcitriol was measured with an immuno-radiometric assay as well
(normal range, 30 to 70 pg/ml), and inulin enzymatically using
inulinase as described by Ku¨hnle, von Dahl and Schmidt [19].
FSIGT data were analyzed using a computer program (MIN-
MOD), which calculates the characteristic metabolic parameters
by fitting glucose and insulin data to the minimal models that
describe the time courses of plasma glucose and insulin concen-
trations [20]. The models assume a first order linear kinetic for
insulin and a glucose-controlled biphasic release from the b-cell.
Both have previously been described in detail [20–22]. The
glucose disappearance model, by accounting for the effect of
insulin and glucose on glucose disappearance, provides two
parameters: SI (min21/(mU/ml)) is the insulin sensitivity index
and SG the glucose effectiveness (min21), that is, the ability of
glucose per se, independent of changes in insulin, to enhance
glucose uptake [22]. The minimal model of insulin appearance in
plasma accounts for the effect of glucose on insulin concentration
during an FSIGT by describing the kinetics of insulin after its
entry into the peripheral circulation. These models provide the
time course of post-hepatic insulin delivery, that is, IDR(t)
(mU/ml/min), and F1 [(mU/ml)min
21/(mg/dl)]. The latter de-
scribes the dynamic (supra-basal) glucose-controlled first phase
post-hepatic insulin delivery and represents a sensitivity index of
early insulin response to a glucose load. The integral over 150
minutes of IDR(t) gives TID (mU/ml in 150 min), which is the
total amount of insulin per unit volume entering the peripheral
circulation during the test. The area under the curve (AUC) for
plasma insulin concentration during the glucose tolerance test
(over 150 min) was calculated using the trapezoidal rule.
Table 1. Clinical data of healthy subjects and of renal patients
Healthy
subjects
Patients plasma creatinine
concentration mg/dl
, 1.3
. 1.3
, 3.0 . 3.0
IgAGN/ADPKD — 12/7 9/7 8/7
Age years 42 6 3a 41 6 2a 46 6 3a 46 6 3a
Gender (m/f) 14/2a 17/2a 15/1a 13/2a
BMI kg/m2 25.2 6 0.8a 25.7 6 1.3a 25.9 6 0.7a 25.4 6 1.1a
Serum creatinine mg/dl 1.0 6 0.1a 1.0 6 0.1a 1.7 6 0.1 4.2 6 0.3
CIn ml/min/1.73 m
2 — 119 6 5 67 6 4 25 6 2
Serum cholesterol mg/dl 180 6 6a 192 6 6a 206 6 6a 212 6 7a
Serum triglycerides mg/dl 87 6 4a 118 6 5ab 142 6 7b 154 6 6b
PTH pmol/liter — 4.7 6 0.4 8.4 6 1.6 39.6 6 7.9
Calcitriol pg/ml — 53 6 3 40 6 3 24 6 2
HCO3 mmol/liter — 25.3 6 0.4
a 24.0 6 0.2a 20.2 6 0.6
Abbreviations are: IgAGN, IgA glomerulonephritis; ADPKD, adult
polycystic kidneay disease; BMI, body mass index; CIn, glomerular filtra-
tion rate by inulin clearance; PTH, intact plasma parathyroid hormone
concentration; HCO3, plasma bicarbonate concentration. The statistical
differences are given at a P level of 0.05 only; shared superscripts are not
significantly different.
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Statistics
The SPSS package was used for statistical analysis. After testing
for normality of data distribution, the data of healthy subjects and
the three groups of patients were compared using a two-tailed
analysis of variance (ANOVA). Bonferroni correction was ap-
plied. Pearson’s correlation analysis between SI on the one hand
and age, BMI, basal (fasted) plasma insulin concentration, AUC,
TID, GFR, PTH, calcitriol, cholesterol and triglyceride concen-
tration on the other hand was done in pooled patient data only.
All data are presented as mean 6 SEM. Differences were consid-
ered as significant at a P level of 0.05.
RESULTS
Table 2 shows the results of the intravenous glucose tolerance
test (minimal model). Insulin sensitivity (mean SI), was markedly
lower in all groups of patients than in healthy subjects. The
difference between the combined results of all patients and
healthy subjects was highly significant (P , 0.001; Fig. 1). In
parallel, mean fasted plasma inulin concentration, AUC and TID
were higher in patients as compared with healthy subjects, reflect-
ing concomitant hyperinsulinemia. There was a trend for insulin
secretion to be less in patients with most advanced renal failure,
however.
There was no significant difference in SI between the three
groups of patients, that is, in patients with GFR values within the
normal range, patients with mild to moderate renal failure and
patients with advanced renal failure. As is known in the normal
population the dispersion of SI values was wide. Accordingly,
some patients had a SI within the range observed in healthy
subjects, whereas others were severely insulin resistant (Fig. 1).
The SI in patients was not correlated with GFR (r 5 0.01, P ,
0.52; Fig. 2), PTH (r 5 20.23, P , 0.11) or calcitriol (r 5 20.03,
P , 0.82) concentration, but was significantly correlated with age
(r 5 20.32, P , 0.011), BMI (r 5 20.25, P , 0.042), fasted
plasma insulin concentration (r 5 20.32, P , 0.009), AUC (r 5
20.62, P , 0.0001), TID (r 5 20.34, P , 0.004) and serum
triglyceride (r 5 20.29, P , 0.04) or cholesterol concentrations
(r 5 20.36, P , 0.007). In addition, glucose effectiveness (SG)
and the early phase insulin secretion (F1) were also found to be
disturbed even in patients when GFR values were within the
normal range. These parameters were similarly reduced in all
patient groups as compared with healthy subjects (Table 2). The
separate analysis of patients with immune origin of renal disease
(IgAGN) and patients with non-immune renal disease (ADPKD)
showed no significant differences between the groups (Table 3).
Table 2. Analysis of glucose metabolism using the minimal model
(MINMOD) in healthy subjects and renal patients
Healthy
subjects
Patients plasma creatinine
concentration mg/dl
, 1.3
. 1.3
, 3.0 . 3.0
SI [min21/(mU/ml)] 8.6 6 0.8 5.1 6 0.7a 5.1 6 0.7a 4.7 6 0.6a
SG min21 3 100 2.9 6 0.3 1.7 6 0.2a 1.9 6 0.3a 1.8 6 0.3a
Ib mU/ml 6.1 6 0.8 11.9 6 1.3a 12.1 6 1.5a 10.8 6 1.3a
AUC mU 3 min/ml 2.1 6 0.3a 3.8 6 0.4b 4.1 6 0.6b 3.4 6 0.4ab
TID mU/ml 279 6 27a 497 6 92b 492 6 84b 390 6 56ab
F1 (mU/ml) min
21/
(mg/dl)
5.4 6 0.9 2.4 6 0.5a 2.3 6 0.5a 2.0 6 0.4a
Gb mmol/liter 5.0 6 0.1a 4.9 6 0.2a 5.0 6 0.2a 5.0 6 0.2a
DV % body weight 17.7 6 1.2a 18.8 6 0.8a 18.2 6 0.8a 19.2 6 0.8a
Abbreviations are: SI, insulin sensitivity index; SG, glucose effective-
ness; Ib, basal (fasted) plasma insulin concentration; AUC, area under the
curve for plasma insulin concentration in 150 minutes; TID, total insulin
delivery in 150 minutes; F1, dynamic first phase insulin response to
glucose; Gb, basal plasma glucose concentration; DV, distribution volume
for glucose. The statistical differences are given at a P level of 0.05 only;
shared superscripts are not significantly different.
Fig. 1. Insulin sensitivity index (SI), that is, insulin sensitivity, in healthy
subjects (N 5 16) and in renal patients (N 5 50). The statistical difference
between groups was highly significant (P , 0.001).
Fig. 2. Correlation between insulin sensitivity (insulin sensitivity index,
SI) and glomerular filtration rate (inulin clearance, CIn) in 29 patients
with IgA glomerulonephritis (E) and 21 patients with adult polycystic
kidney disease (F). There was no correlation between both variables (r 5
0.01, P , 0.52).
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Mean SI was reduced in both groups of patients irrespective of the
stage of renal function (Fig. 2), although a trend for less marked
SI reduction was noted in patients with ADPKD.
DISCUSSION
The novel finding in the present study is the demonstration that
in patients with renal disease insulin sensitivity is diminished early
on, even before GFR is below the normal range. A diminished
ability of insulin to stimulate glucose uptake by its target organs,
as documented by a decreased insulin sensitivity index (SI), was
seen even in patients whose GFR values were still within the
normal range, and in whom anemia, metabolic acidosis, secondary
hyperparahyroidism or vitamin D insufficiency were not present.
The SI was significantly lower in renal patients than in matched
controls; and it was not correlated with CIn across a wide range of
GFR values. These findings are in general agreement with
observations of other authors in smaller populations using a
different methodological approach [23, 24]. Fasted insulin con-
centration was increased, presumably as a compensatory mecha-
nism to overcome insulin resistance. Total insulin delivery during
the test calculated using quantitative modeling analysis was also
increased. Furthermore, in patients with renal disease we found
not only a reduction of the ability of insulin to stimulate glucose
uptake (SI), but also a reduction of the ability of glucose to
stimulate glucose uptake (SG). Finally, our patients exhibited a
reduced beta cell responsivness to glucose during the first phase,
reflected by the decreased sensitivity (F1) to glucose. By delaying
delivery of insulin to the liver and the attendent inhibition of liver
glucose production, this alteration should promote hyperglycemia
as in patients with type 2 (non-insulin dependent) diabetes
mellitus [20, 25], althought the reduction of hepatic glucose
production by exogenous insulin is not affected in patients with
renal failure [2]. In contrast to patients with type 2 diabetes, in
whom the metabolic abnormalities become more severe as the
disease progresses, in this cross sectional study no clearcut
evidence of progression in the severity of insulin resistance was
found in renal patients with increasingly lower GFR (CIn),
although there was a trend for stimulated insulin secretion to be
less in patients with most advanced renal failure. Longitudinal
studies are required to define the evolution of the disturbances in
glucose metabolism with time in patients with progressive renal
disease. In this respect it is of interest that higher triglyceride
levels were present in patients with normal GFR, and the increase
in serum triglyceride concentration was even more marked in
patients with advanced renal failure. These data are in good
agreement with observations of previous studies [14].
Evidence of insulin resistance was found both in patients with
immune (IgAGN) and non-immune (ADPKD) renal disease. The
finding in the former group excluded the possibility that abnormal
glucose metabolism is part of the ADPKD phenotype [24]. It
appears paradoxical that in patients with renal disease insulin
resistance should be present even though GFR values are still
within the normal range. We caution, however, that apparently
normal renal function, as documented by GFR values within the
normal range, does not necesserily exclude reduction of functional
parenchyma by the disease process. Adaptive changes in glomer-
ular filtration dynamics may keep GFR within the normal range
despite considerable reduction of tubular cell mass, and this could
be causally related to the abnormalities in glucose metabolism. An
alternative explanation for the early presence of such abnormal-
ities of the glucose metabolism may be genetic and/or enviromen-
tal factors. For instance, a higher frequency of hypertension (and
of metabolic syndrome?) is found in families of patients with
IgAGN [26]. Another point to consider is abnormal skeletal
muscle composition in patients with renal failure [27]; this is
reminiscent of findings in patients with the metabolic syndrome,
that is, in patients with several derangements of glucose and lipid
metabolism, who are prone to develop type 2 diabetes mellitus
[28].
In contrast to insulin sensitivity (which is reduced to the same
extent in patients with normal GFR values and in patients with
reduced GFR) a tendency for less insulin secretion is seen only in
patients with severely compromised renal function. Experimental
data suggest that PTH and increased intracellular calcium con-
centration are involved in the impairment of insulin secretion of
renal failure [29, 30]. Support for this assumption also comes from
studies in uremic patients with secondary hyperparathyroidismus
in whom parathyroidectomy ameliorates the abnormalities of
insulin secretion [31, 32]. In studies of patients on maintainance
hemodialysis a significant correlation was found between in-
creased PTH concentrations (and platelet intracellular calcium)
and impaired glucose tolerance, but parathyroidectomy did not
affect insulin sensitivity [11, 31, 32]. In our patients PTH concen-
trations were not significantly correlated with insulin sensitivity,
but it must be acknowledged that the sensitivity of this cross-
sectional statistical approach is limited. Nevertheless, the absence
of an effect of PTH on insulin sensitivity would be in agreement
with our own finding in healthy subjects in whom under conditions
of euglycemic hyperinsulinemia subacute administration of hu-
man 1,34-PTH did not affect insulin sensitivity, despite a signifi-
cant increase of platelet intracellular calcium concentration and
arterial blood pressure [33]. These observations do not definitely
exclude a role of PTH, but suggest that any potential role of PTH
must be minor compared to other factors that may impact on
glucose metabolism. The same consideration applies for the role
of calcitriol in the disturbances of glucose metabolism in renal
patients. Calcitriol concentrations were within the normal range
in patients with normal renal function in whom marked insulin
resistance was present. Another factor that might be involved in
Table 3. Results in patients with immune (IgAGN) and non-immune
renal disease (ADPKD) according to degree of renal function
Plasma creatinine concentration mg/dl
, 1.3
. 1.3
, 3.0 . 3.0
Patients with IgAGN
Age years 44 6 3a 46 6 2a 43 6 3a
BMI kg/m2 25.6 6 1.3a 26.0 6 0.6a 25.7 6 1.2a
SI min21/(mU/ml) 4.9 6 0.6a 4.9 6 0.6a 4.7 6 0.6a
TID mU/ml 530 6 94a 497 6 76a 417 6 63a
Patients with ADPKD
Age years 35 6 2 47 6 3a 50 6 3a
BMI kg/m2 25.8 6 1.3a 25.8 6 0.8a 25.2 6 1.0a
SI min21/(mU/ml) 5.3 6 0.7a 5.3 6 0.5a 4.8 6 0.7a
TID mU/ml 477 6 49a 480 6 73a 373 6 47a
Abbreviations are: BMI, body mass index; SI, insulin sensitivity index;
TID, total insulin delivery in 150 minutes. The statistical differences are
given at a P level of 0.05 only; shared superscripts are not significantly
different.
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derangements of glucose metabolism in renal patients is sympa-
thetic activity, which is increased even in early renal disease, such
as in patients with a plasma creatinine concentration below 1.6
mg/dl [34].
In the present study we observed considerable variability of the
SI in healthy controls and in renal patients, leading to an overlap
of SI values between the group of patients and the group of
controls. Such variability of insulin sensitivity was found not only
in healthy subjects but also in several conditions with insulin
resistance, such as type 2 diabetes mellitus, obesity, etc. [28, 35,
36]. It is thought to reflect interaction of multiple genetic and
non-genetic factors determining insulin sensitivity in the general
population and by implication also in individuals with impaired
insulin sensitivity, such as renal patients.
In conclusion, insulin resistance and hyperinsulinemia are
present very early in the course of renal disease, even when GFR
values are still within the normal range. These observations may
have potential implications for the management of renal patients.
The link between insulin resistance, cardiovascular risk factors
and cardiac mortality has been documented in patients with the
metabolic syndrome. It is reasonable to assume that in renal
failure, another example of insulin resistance, a similar link exists.
Interventions should presumably be initiated very early on to
correct the potentially atherogenic metabolic profile in order to
improve survival of patients in the predialytic phase and prevent
atherosclerotic disease at the time of entry into dialysis.
Reprint requests to Danilo Fliser, M.D., Division of Nephrology, Depart-
ment of Internal Medicine, Ruperto-Carola-University, Bergheimerstr. 56a,
69115 Heidelberg, Germany.
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